Movements at UCB Pharma Canada and a resignation at GeoVax – People on the move

in-PharmaTechnologist presents its latest roundup of appointments in the pharmaceutical sector, including movements at UCB Pharma Canada and a resignation at GeoVax.

UCB PharmaCanada has appointed Anne de Cassini as its general manager. In the capacity de Cassini will lead the company’s efforts to become a biotech leader in Canada.

Prior to the promotion de Cassini was UCB’s general manager of central nervous system business operations in France. She has 22 years experience in the pharma industry.

UK-based packaging company Brecon Pharmaceuticals, a subsidiary of AmerisourceBergen, has appointed Peter Beldon as its executive vice president and managing director.

Beldon will lead the company’s European operations. He has previously worked at Anderson Packaging for seven years.

Andrew Kandalepas, senior vice president and director at GeoVax, has resigned. GeoVax has said that it is seeking a consulting arrangement with Kandalepas so that he can continue to help the company.

PhotoMedex has appointed Dennis McGrath as its CEO following the resignation of Jeffrey O’Donnell from the post. O’Donnell held the position since 1999. McGrath joined PhotoMedex in 2000as chief financial officer (CFO).

Antares Pharma has promoted three members of staff. Robert Apple is now executive vice president, CFO and president of the parenteral products division.

In addition Kaushik Dave is now senior vice president product development and Peter Sadowski has been promoted to senior vice president of the parenteral products division.

DOR BioPharma has appointed Christopher Schnittker, as vice president of administration and controller. Schnittker has more than 18 years financial management experience, primarily in publically held life science companies.

Sunil Patel has been appointed as senior vice president, corporate development at OncoMed Pharmaceuticals. Patel has 15 years experience in the biotech industry at companies including BiPar Sciences, Gilead Sciences and Allos Therapeutics.